Oklahoma.

Yes. Under the Oklahoma Telemedicine Act, a licensed Oklahoma provider may establish a patient relationship and prescribe non-controlled medications like semaglutide through telehealth, including asynchronous review of your intake, as long as the standard of care is met. You do not need a prior in-person visit.

SoonerCare (Oklahoma Medicaid) covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited, and compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid coverage does not apply to our prescriptions.

Yes. Compounded semaglutide prescribed by an Oklahoma-licensed provider and dispensed by a US state-licensed compounding pharmacy is legal when prepared for an individual patient with a documented clinical need. Pallas works only with US state-licensed 503A and 503B compounding pharmacies.

Most Oklahoma patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Oklahoma City, Tulsa, and Norman typically ship fastest; rural ZIP codes may take an extra day.

Pallas is a cash-pay telehealth service — there is no insurance to bill and no membership fee to join. Before you pay anything, you see a flat all-in price during intake that covers the medication, your clinician's review, and shipping to your Oklahoma address. The price you see is the price you pay — no surprise renewal markups — and multi-month plans lower the per-month cost compared with paying month to month. The price is the same whether you are in Oklahoma City, Tulsa, or a rural Oklahoma ZIP code.

Eligibility is always decided by an Oklahoma-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your Oklahoma-licensed provider.

Yes, many patients transfer their care to Pallas. During intake you tell your clinician which medication and dose you take now and how you have tolerated it. Your Oklahoma-licensed provider reviews that history and, if appropriate, continues you at a comparable dose or adjusts your titration plan. Do not stop or change a prescription on your own — let your clinician guide any transition.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the Oklahoma State Board of Medical Licensure and Supervision reviews it asynchronously in most cases — no live video required — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any Oklahoma address, usually within 2–3 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team, change your plan, or cancel anytime from your patient portal — no phone calls or retention hoops.